Acrongenomics, Inc. (AGNM) is a publicly traded company that focuses on developing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-oriented applications.

Following a primary market research, a number of potential POC diagnostic device applications were evaluated in terms of feasibility, market needs, revenue generating potential, market growth rate and competition. Among these, four disease areas were chosen to be our primary targets for BioLED device development. These POC devices will enable on-the-spot quantitative and qualitative diagnosis from a few drops of blood, urine or saliva for:

Diabetes Management (Kidney Markers): The prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (Global Prevalence of Diabetes. Diabetes Care 27:1047-1053, 2004). Microalbuminuria (MAU), a well known diabetic nephropathy marker, is defined by increased urinary Human Serum Albumin (HSA) excretion. If diagnosed at an early stage, MAU can be treated before its progression to the development of diabetic nephropathy (kidney failure). Approximately 25-30% of all diabetics develop evidence of nephropathy.

We are on the final stage of developing chips for the detection of Microalbuminuria, (albumine/creatinine in urine).

Cardiovascular Diseases (Cardiac Markers): Cardiovascular diseases are responsible for the deaths of 17 milion people worldwide each year, making them the developed world's leading cause of death according to the World Health Organization. 32 million heart attacks and strokes per year demonstrate the need for the development of accurate, cost efficient and accessible diagnostics. Conventional diagnostic techniques, however, are costly, time consuming and of limited predictive potential. A smarter diagnostic approach is the in vitro measurement of various cardiac biomarkers of high preventive value, using a POC device. We are developing chips for: CK-MB and Myoglobin in whole blood.